Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cy7.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  2. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  3. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  4. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  5. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  6. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  7. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  8. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  9. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  10. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  11. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  12. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  13. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  14. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  15. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  16. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  17. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  18. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  19. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  20. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  21. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  22. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  23. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  24. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  25. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  26. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  27. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  28. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  29. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  30. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  31. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  32. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  33. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  34. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  35. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  36. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  37. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  38. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  39. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  40. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  41. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  42. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  43. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  44. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  45. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  46. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  47. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  48. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  49. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  50. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  51. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  52. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  53. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  54. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  55. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  56. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  57. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  58. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  59. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  60. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  61. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  62. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  64. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  65. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  66. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  67. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  68. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  69. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  70. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  71. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  72. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  73. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  74. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  75. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  76. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  77. Woodruff MC, et al. 2022. Nature. :. PubMed
  78. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  79. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  80. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  81. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  82. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  83. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  84. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  85. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  86. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  87. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  88. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  89. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  90. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  91. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  92. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  93. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  94. Akiyama H, et al. 2020. J Virol. . PubMed
  95. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  96. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  97. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  98. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  99. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  100. Mills C, et al. 2022. Cells. 11:. PubMed
  101. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  102. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  103. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  104. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  105. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  106. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  107. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  108. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  109. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  110. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  111. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  112. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  113. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  114. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  115. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  116. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  117. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  118. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  119. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  120. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  121. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  122. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  123. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  124. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  125. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  126. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  127. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  128. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  129. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  130. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  131. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  132. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  133. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  134. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  135. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  136. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  137. Wang Z, et al. 2021. bioRxiv. . PubMed
  138. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  139. English KG, et al. 2022. Biomedicines. 10:. PubMed
  140. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  141. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  142. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  143. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  144. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  145. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  146. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  147. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  148. Woodruff M, et al. 2020. medRxiv. . PubMed
  149. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  150. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  151. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  152. Popay TM, et al. 2021. Elife. 10: . PubMed
  153. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  154. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  155. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  156. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  157. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  158. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  159. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  160. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  161. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  162. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  163. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  164. Ito Y, et al. 2018. Cell. 174:636. PubMed
  165. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  166. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  167. Elias G, et al. 2022. Elife. 11:. PubMed
  168. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  169. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  170. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  171. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  172. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  173. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  174. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  175. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  176. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  177. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  178. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  179. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  180. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  181. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  182. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  183. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  184. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  185. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  186. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  187. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  188. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  189. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  190. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  191. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  192. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  193. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  194. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  195. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  196. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  197. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  198. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  199. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  200. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  201. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  202. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  203. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  204. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  205. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  206. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  207. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  208. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  209. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  210. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  211. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  212. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  213. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  214. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  215. Wang Z, et al. 2021. Nature. 592:616. PubMed
  216. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  217. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  218. Dudek M, et al. 2021. Nature. 592:444. PubMed
  219. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  220. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  221. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  222. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  223. He Y, et al. 2022. Cells. 11:. PubMed
  224. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  225. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  226. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  227. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  228. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  229. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  230. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  231. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  232. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  233. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  234. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  235. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  236. Wang Z, et al. 2021. Nature. 595:426. PubMed
  237. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  238. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  239. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  240. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  241. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  242. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  243. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  244. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  245. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  246. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  247. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  248. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  249. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  250. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  251. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  252. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  253. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  254. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  255. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  256. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  257. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  258. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  259. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  260. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  261. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  262. Korin B, et al. 2020. Sleep. :43. PubMed
  263. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  264. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  265. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  266. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  267. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  268. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  269. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  270. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  271. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  272. Viant C, et al. 2020. Cell. 183:1298. PubMed
  273. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  274. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  275. Gaebler C, et al. 2020. bioRxiv. . PubMed
  276. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  277. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  278. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  279. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  280. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  281. Sibler E, et al. 2021. Cells. 10:. PubMed
  282. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  283. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  284. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  285. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  286. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  287. Spath S, et al. 2022. iScience. 25:104998. PubMed
  288. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  289. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  290. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  291. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  292. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  293. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  294. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  295. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  296. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  297. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  298. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  299. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  300. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  301. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  302. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  303. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  304. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  305. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  306. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  307. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 5    Revision Date: 05-20-2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account